Overview

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Cisplatin
Pemetrexed